Schonfeld Strategic Advisors LLC Biomarin Pharmaceutical Inc Transaction History

Schonfeld Strategic Advisors LLC

$14.6 Billion
Q2 2024

A detailed history of Schonfeld Strategic Advisors LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 204,432 shares of BMRN stock, worth $14.4 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares

204,432

Previous 182,492 12.02%

Holding current value

$14.4 Million

Previous $15.9 Million 5.6%

% of portfolio

0.12%

Previous 0.11%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$74.43 - $92.22 $1.63 Million - $2.02 Million	21,940 Added 12.02%	204,432 $16.8 Million
Q1 2024 May 15, 2024	BUY	$83.81 - $99.0 $949,734 - $1.12 Million	11,332 Added 6.62%	182,492 $15.9 Million
Q4 2023 Feb 14, 2024	BUY	$76.22 - $98.51 $5.8 Million - $7.5 Million	76,159 Added 80.17%	171,160 $16.5 Million
Q3 2023 Nov 14, 2023	BUY	$85.07 - $94.48 $3.11 Million - $3.46 Million	36,574 Added 62.6%	95,001 $8.41 Million
Q2 2023 Aug 14, 2023	BUY	$86.68 - $100.3 $3.95 Million - $4.57 Million	45,540 Added 353.38%	58,427 $5.06 Million
Q1 2023 May 15, 2023	SELL	$87.74 - $117.27 $5.04 Million - $6.73 Million	-57,400 Reduced 81.67%	12,887 $1.25 Million
Q4 2022 Feb 14, 2023	SELL	$80.93 - $108.63 $2.15 Million - $2.89 Million	-26,569 Reduced 27.43%	70,287 $7.27 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $7.73 Million - $9.12 Million	94,063 Added 3367.81%	96,856 $8.21 Million
Q2 2022 Aug 15, 2022	SELL	$71.48 - $86.85 $2.53 Million - $3.08 Million	-35,407 Reduced 92.69%	2,793 $231,000
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $2.84 Million - $3.54 Million	38,200 New	38,200 $2.95 Million
Q4 2021 Feb 14, 2022	SELL	$71.72 - $91.47 $2.1 Million - $2.68 Million	-29,300 Closed	0 $0
Q3 2021 Nov 16, 2021	BUY	$74.77 - $85.47 $1.27 Million - $1.45 Million	17,001 Added 138.23%	29,300 $2.27 Million
Q2 2021 Aug 16, 2021	BUY	$75.51 - $84.79 $928,697 - $1.04 Million	12,299 New	12,299 $1.03 Million
Q1 2021 May 17, 2021	SELL	$74.73 - $90.69 $1.39 Million - $1.68 Million	-18,541 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$72.61 - $90.2 $1 Million - $1.24 Million	13,788 Added 290.09%	18,541 $1.63 Million
Q3 2020 Nov 16, 2020	SELL	$71.87 - $131.03 $340,304 - $620,427	-4,735 Reduced 49.91%	4,753 $362,000
Q2 2020 Aug 14, 2020	BUY	$79.55 - $124.22 $249,627 - $389,802	3,138 Added 49.42%	9,488 $1.17 Million
Q1 2020 May 15, 2020	BUY	$71.37 - $96.85 $453,199 - $614,997	6,350 New	6,350 $537,000
Q4 2019 Feb 14, 2020	SELL	$64.27 - $86.37 $2.87 Million - $3.86 Million	-44,700 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$67.4 - $85.11 $2.49 Million - $3.15 Million	37,000 Added 480.52%	44,700 $3.01 Million
Q2 2019 Aug 14, 2019	BUY	$80.35 - $93.9 $618,695 - $723,030	7,700 New	7,700 $660,000
Q4 2018 Feb 14, 2019	SELL	$80.14 - $106.07 $1.35 Million - $1.79 Million	-16,900 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$93.92 - $105.72 $6.47 Million - $7.28 Million	-68,900 Reduced 80.3%	16,900 $1.64 Million
Q2 2018 Aug 14, 2018	BUY	$76.01 - $99.03 $6.52 Million - $8.5 Million	85,800 New	85,800 $8.08 Million

Others Institutions Holding BMRN

# of Institutions

632

Shares Held

185M

Call Options Held

1.63M

Put Options Held

1.2M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.

Account

Schonfeld Strategic Advisors LLC Biomarin Pharmaceutical Inc Transaction History